title: Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients.
authors.forename: Zoraida
authors.initials: Z
authors.lastname: Verde
authors.forename: Catalina
authors.initials: C
authors.lastname: Santiago
authors.forename: Beatriz
authors.initials: B
authors.lastname: Valle
authors.forename: Ana
authors.initials: A
authors.lastname: Fernández-Santander
authors.forename: Fernando
authors.initials: F
authors.lastname: Bandrés
authors.forename: Elpidio
authors.initials: E
authors.lastname: Calvo
authors.forename: Jonatan R
authors.initials: JR
authors.lastname: Ruiz
authors.forename: Alejandro
authors.initials: A
authors.lastname: Lucía
authors.forename: Félix Gómez
authors.initials: FG
authors.lastname: Gallego
mesh_terms: D000074:Acenocoumarol / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D011110:Polymorphism, Genetic; D012307:Risk Factors; D064417:Vitamin K Epoxide Reductases
chemical_list: D000925:Anticoagulants; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases; D000074:Acenocoumarol